CymaBay Therapeutics, Inc.
(NASDAQ : CBAY)

( )
CBAY After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading CBAY News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.96%73.420.9%$713.07m
AMGNAmgen Inc.
0.08%179.321.1%$583.83m
CELGCelgene Corporation
0.97%136.311.1%$571.96m
REGNRegeneron Pharmaceuticals, Inc.
2.83%521.132.7%$511.51m
VRTXVertex Pharmaceuticals Incorporated
-0.23%159.331.9%$392.76m
BIIBBiogen Inc.
-0.18%281.441.2%$388.90m
ALXNAlexion Pharmaceuticals, Inc.
1.97%129.811.9%$272.80m
TSROTESARO, Inc.
4.02%129.0114.7%$168.19m
INCYIncyte Corporation
2.56%133.792.6%$164.97m
ILMNIllumina, Inc.
-1.10%171.973.5%$156.83m
EXELExelixis, Inc.
0.90%26.996.5%$154.24m
CLVSClovis Oncology, Inc.
1.69%85.2718.0%$152.78m
BMRNBioMarin Pharmaceutical Inc.
0.59%87.744.4%$131.34m
KITEKite Pharma, Inc.
4.23%109.8916.1%$121.79m
BLUEBluebird Bio, Inc.
-1.54%95.8019.3%$109.71m

Company Profile

CymaBay Therapeutics, Inc. is a clinical stage company, which engages in the research and development of biopharmaceutical products. Its candidates include MBX-8025 and Arhalofenate. MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.